Blair William & Co. IL Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Blair William & Co. IL lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 42.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,742 shares of the medical research company's stock after buying an additional 1,699 shares during the period. Blair William & Co. IL's holdings in IQVIA were worth $1,128,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC bought a new position in shares of IQVIA during the third quarter valued at about $223,000. Captrust Financial Advisors grew its position in IQVIA by 30.8% during the 3rd quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company's stock worth $1,940,000 after acquiring an additional 1,927 shares during the last quarter. Benjamin Edwards Inc. bought a new stake in IQVIA in the third quarter valued at approximately $261,000. Hilltop Holdings Inc. purchased a new stake in shares of IQVIA during the third quarter valued at approximately $446,000. Finally, HighTower Advisors LLC grew its holdings in shares of IQVIA by 6.3% in the third quarter. HighTower Advisors LLC now owns 142,031 shares of the medical research company's stock worth $33,640,000 after purchasing an additional 8,436 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 1.3 %

IQV stock traded down $2.02 on Monday, reaching $152.72. 3,383,268 shares of the company traded hands, compared to its average volume of 1,331,643. The firm has a fifty day simple moving average of $188.58 and a 200-day simple moving average of $202.90. The company has a market cap of $26.93 billion, a P/E ratio of 20.36, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $146.06 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IQV shares. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Barclays reduced their price target on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.